De Novo or Increasing Lower Urinary Tract Symptoms during COVID-19 Infection: Long-term Results

Background: How COVID-19 affects lower urinary tract symptoms (LUTS) in men has not been demonstrated by published research. This study examined the de novo development of LUTS and the change in the severity of pre-existing LUTS in men hospitalized with COVID-19. A follow-up period of 12 months after COVID-19 infection provided data on the long-term effect of COVID-19 vs. LUTS. Methods: Data were collected from 70 male patients diagnosed with COVID-19 via nasopharyngeal swab RT-PCR technology between June 2020 and April 2021. The patient’s age, comorbidities, date of COVID-19 diagnosis, date of LUTS, International Prostate Symptom Score (IPSS), prostate-specific antigen (PSA), creatinine, and D-dimer levels, urinalysis, urine culture and duration of hospital stay were recorded. Statistical analyses were conducted to compare between pre-COVID and post-COVID IPSS and other data. Results: 42 patients were included in this study with a, mean age of patients were 54.76 $\pm$ 11.95 years. In 8 patients there was no change in IPSS pre- vs. post-COVID. In the remaining 34 patients (80.9%), the median IPSS increased from a pre-COVID value of 2 to 10 during COVID (p $<$ 0.001). In the subgroup analysis based on age $<$50 years vs. $\ge$50 years, statistically significant increase in IPSS were found in both age groups pre- and post-COVID. Conclusions: In male patients of all ages, COVID-19 results in the de novo occurrence of LUTS and an increase in pre-existing LUTS in approximately 80% of patients. These symptoms were found to persist at a 12-months follow-up.

cohort; COVID-19; IPSS; LUTS; observational study; urinary tract

[1] World Health Organization. Coronavirus disease (COVID-2019) situation reports. World Health Organization. 2020. Avail-able at: https://www.who.int/emergencies/diseases/novel-coron avirus-2019/situation-reports (Accessed: 9 February 2022).

[2] WHO Coronavirus (COVID-19) Dashboard. 2019. Available at: https://covid19.who.int (Accessed: 9 February 2022 ).

[3] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. Journal of the American Medical Association. 2020; 323: 1061–1069.

[4] Archer JE, Odeh A, Ereidge S. Mortality and pulmonary compli-cations in patients undergoing surgery with perioperative SARS-CoV2 infection: an international cohort study. The Lancet. 2020; 396: 27–38.

[5] Song JY, Yun JG, Noh JY, Cheong HJ, Kim WJ. COVID-19 in South Korea—Challenges of Subclinical Manifestations. New England Journal of Medicine. 2020; 382: 1858–1859.

[6] Leung JM, Yang CX, Tam A, Shaipanich T, Hackett T, Singhera GK, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eu-ropean Respiratory Journal. 2020; 55: 2000688.

[7] Peng L, Liu J, Xu W, Luo Q, Deng K, Lin B, et al. 2019 Novel coronavirus can be detected in urine, blood, anal swabs and oropharyngeal swabs samples. To be published in medRxiv. 2020. (in press)

[8] Lo IL, Lio CF, Cheong HH, Lei CI, Cheong TH, Zhong X, etal. Evaluation of SARS-CoV-2 RNA shedding in clinical speci-mens and clinical characteristics of 10 patients with COVID-19 in Macau. International Journal of Biological Sciences. 2020; 16: 1698.

[9] Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. Journal of the American Medical Association. 2020; 323: 1843e4.

[10] Lamb LE, Dhar N, Timar R, Wills M, Dhar S, Chancellor MB. COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Medical Hypothe-ses. 2020; 145: 110375.

[11] Can O, Erkoç M, Ozer M, Karakanli MU, Otunctemur A. The effect of COVID‐19 on lower urinary tract symptoms in el-derly men. International Journal of Clinical Practice. 2021; 75: e14110.

[12] Kaya Y, Kaya C, Kartal T, Tahta T, Tokgöz VY. Could LUTS be early symptoms of COVID-19. International Journal of Clinical Practice. 2021; 75: e13850.

[13] Güçlü E, Koroglu M, Yürümez Y, Toptan H, Kose E, Güneysu F, et al. Comparison of saliva and oro-nasopharyngeal swab sam-ple in the molecular diagnosis of COVID-19. Revista da Asso-ciacao Medica Brasileira. 2020; 66: 1116–1121.

[14] Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in pa-tients with viral pneumonia. Emerging Microbes and Infections. 2020; 9: 727–732.

[15] Mumm J, Osterman A, Ruzicka M, Stihl C, Vilsmaier T, Munker D, et al. Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: does SARS-CoV-2 Cause Viral Cystitis?European Urology. 2020; 78: 624–628.

[16] Karabulut I, Cinislioglu A, Cinislioglu N, Yilmazel F, Utlu M, Alay H, et al. The Effect of the Presence of Lower Urinary Sys-tem Symptoms on the Prognosis of COVID-19: Preliminary Re-sults of a Prospective Study. Urologia Internationalis. 2020; 104: 853–858.

[17] Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P, et al. Comprehensive overview of prostatitis. Biomedicine and Pharmacotherapy. 2017; 94: 1064–1076.

[18] McKay TC, Albala DM, Sendelbach K, Gattuso P. Cy-tomegalovirus prostatitis. Case report and review of the litera-ture. International Urology and Nephrology. 1994; 26: 535–540.

[19] Yoon GS, Nagar MS, Tavora F, Epstein JI. Cytomegalovirus Prostatitis: a Series of 4 Cases. International Journal of Surgical Pathology. 2010; 18: 55–59.